• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤细胞内在的BIN1缺陷通过G3BP1介导的STAT1降解促进非小细胞肺癌的免疫抑制并阻碍铁死亡。

Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1.

作者信息

Wang Jiali, Jia Yunlong, Liu Tianxu, Liu Xinyan, Yin Shuxian, Chen Jiaqi, Xu Xiaoqing, Zhang Yi, Liu Lihua

机构信息

Department of Tumor Immunotherapy, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, 050035, P.R. China.

Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, 100053, China.

出版信息

J Exp Clin Cancer Res. 2025 May 9;44(1):141. doi: 10.1186/s13046-025-03404-9.

DOI:10.1186/s13046-025-03404-9
PMID:40346580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12063428/
Abstract

BACKGROUND

Tumors often evade immune surveillance by limiting T cell infiltration. In non-small cell lung cancer (NSCLC), increased infiltration of CD8 T cells is associated with a favorable response to immunotherapy. While BIN1 is recognized as a tumor suppressor gene, its role in shaping the tumor microenvironment in NSCLC has yet to be fully clarified.

METHODS

To investigate the relationship between BIN1 expression and CD8T cell infiltration in NSCLC, we performed a comprehensive data analysis utilizing clinical information from NSCLC patients. BIN1 expression levels in NSCLC tissues were evaluated, and their correlation with CD8T cells infiltration and patient survival outcomes was examined. Loss-of-function strategies targeting BIN1 were applied in syngeneic NSCLC mouse models to assess its functional significance. Tumor growth was monitored, and immune cell populations were analyzed in terms of frequency and functionality through mass cytometry and flow cytometry techniques. Cytokine secretion was profiled using multiplex assays. Additionally, RNA sequencing, immunoprecipitation-mass spectrometry, and molecular docking were employed to confirm direct interactions between BIN1 and cytokine-encoding genes. Finally, the regulatory role of BIN1 in ferroptosis in NSCLC cells were explored using metabolomics analysis, ROS measurement, and MDA detection.

RESULTS

We observed that BIN1 expression is downregulated in NSCLC tumor tissues, with its reduced expression strongly associated with advanced disease progression and poor prognosis. Bioinformatics analysis of immune infiltration in human NSCLC samples revealed a positive correlation between BIN1 expression in NSCLC tissues and CD8 T cell infiltration. Furthermore, the prognostic impact of BIN1 on NSCLC patients is strongly linked to the level of CD8 T cell infiltration. In syngeneic mouse models, the knockout of BIN1 in NSCLC cells significantly inhibited CD8 T cell infiltration and impaired their cytotoxic function, facilitating tumor immune evasion. Mechanistically, we demonstrated that BIN1 directly interacts with G3BP1, and its knockout stabilizes G3BP1. This, in turn, promotes STAT1 degradation and reduces the secretion of T cell-recruiting chemokines such as CXCL10 and CCL5. Finally, our findings reveal that BIN1 influences ferroptosis in NSCLC cells through the G3BP1/STAT1/GSH pathway, thereby regulating NSCLC cell proliferation, migration, and invasion.

CONCLUSION

This study highlights the crucial role of the BIN1/G3BP1/STAT1/CD8 tumor-infiltrating lymphocyte signaling pathway in the progression of NSCLC and its mechanisms of immune evasion. This fundings lay a foundation for the development of BIN1-targeted therapies aimed at improving tumor immunogenicity and transforming immunologically "cold" NSCLC into a more responsive disease.

摘要

背景

肿瘤常常通过限制T细胞浸润来逃避免疫监视。在非小细胞肺癌(NSCLC)中,CD8 T细胞浸润增加与免疫治疗的良好反应相关。虽然BIN1被认为是一种肿瘤抑制基因,但其在NSCLC肿瘤微环境形成中的作用尚未完全阐明。

方法

为了研究BIN1表达与NSCLC中CD8 T细胞浸润之间的关系,我们利用NSCLC患者的临床信息进行了全面的数据分析。评估了NSCLC组织中BIN1的表达水平,并检查了其与CD8 T细胞浸润及患者生存结果的相关性。在同基因NSCLC小鼠模型中应用针对BIN1的功能缺失策略,以评估其功能意义。监测肿瘤生长,并通过质谱流式细胞术和流式细胞术技术分析免疫细胞群体的频率和功能。使用多重检测分析细胞因子分泌情况。此外,采用RNA测序、免疫沉淀-质谱分析和分子对接来确认BIN1与细胞因子编码基因之间的直接相互作用。最后,利用代谢组学分析、活性氧测量和丙二醛检测,探索BIN1在NSCLC细胞铁死亡中的调节作用。

结果

我们观察到NSCLC肿瘤组织中BIN1表达下调,其表达降低与疾病进展和预后不良密切相关。对人类NSCLC样本的免疫浸润进行生物信息学分析发现,NSCLC组织中BIN1表达与CD8 T细胞浸润呈正相关。此外,BIN1对NSCLC患者的预后影响与CD8 T细胞浸润水平密切相关。在同基因小鼠模型中,敲除NSCLC细胞中的BIN1可显著抑制CD8 T细胞浸润并损害其细胞毒性功能,促进肿瘤免疫逃逸。机制上,我们证明BIN1直接与G3BP1相互作用,其敲除使G3BP1稳定。这反过来又促进STAT1降解,并减少CXCL10和CCL5等T细胞招募趋化因子的分泌。最后,我们的研究结果表明,BIN1通过G3BP1/STAT1/谷胱甘肽途径影响NSCLC细胞的铁死亡,从而调节NSCLC细胞的增殖、迁移和侵袭。

结论

本研究强调了BIN1/G3BP1/STAT1/CD8肿瘤浸润淋巴细胞信号通路在NSCLC进展及其免疫逃逸机制中的关键作用。这些发现为开发旨在提高肿瘤免疫原性并将免疫“冷”的NSCLC转变为更易反应疾病的BIN1靶向治疗奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/f3c7b7270faa/13046_2025_3404_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/f6c29ac26a59/13046_2025_3404_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/6d5acd89cf3e/13046_2025_3404_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/a67e9d4c61a4/13046_2025_3404_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/d63439427fd1/13046_2025_3404_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/2a585ab51256/13046_2025_3404_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/b33a29f678fc/13046_2025_3404_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/c9c684996bfd/13046_2025_3404_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/f3c7b7270faa/13046_2025_3404_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/f6c29ac26a59/13046_2025_3404_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/6d5acd89cf3e/13046_2025_3404_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/a67e9d4c61a4/13046_2025_3404_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/d63439427fd1/13046_2025_3404_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/2a585ab51256/13046_2025_3404_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/b33a29f678fc/13046_2025_3404_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/c9c684996bfd/13046_2025_3404_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8f/12063428/f3c7b7270faa/13046_2025_3404_Fig8_HTML.jpg

相似文献

1
Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1.肿瘤细胞内在的BIN1缺陷通过G3BP1介导的STAT1降解促进非小细胞肺癌的免疫抑制并阻碍铁死亡。
J Exp Clin Cancer Res. 2025 May 9;44(1):141. doi: 10.1186/s13046-025-03404-9.
2
N-methyladenosine-modified circIGF2BP3 inhibits CD8 T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.N6-甲基腺苷修饰的环状 IGF2BP3 通过促进非小细胞肺癌中 PD-L1 的去泛素化来抑制 CD8 T 细胞反应,从而促进肿瘤免疫逃逸。
Mol Cancer. 2021 Aug 20;20(1):105. doi: 10.1186/s12943-021-01398-4.
3
Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.靶向 SNORA38B 通过调控 GAB2/AKT/mTOR 信号通路重塑肿瘤微环境,抑制非小细胞肺癌的肿瘤发生并增强免疫检查点阻断作用。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2021-004113.
4
COPS6 promotes tumor progression and reduces CD8 T cell infiltration by repressing IL-6 production to facilitate tumor immune evasion in breast cancer.COPS6 通过抑制 IL-6 的产生促进肿瘤进展并减少 CD8 T 细胞浸润,从而促进乳腺癌的肿瘤免疫逃逸。
Acta Pharmacol Sin. 2023 Sep;44(9):1890-1905. doi: 10.1038/s41401-023-01085-8. Epub 2023 Apr 24.
5
Tumor cell-intrinsic circular RNA circFNDC3B attenuates CD8 T cells infiltration in non-small cell lung cancer.肿瘤细胞内在的环状RNA circFNDC3B减弱非小细胞肺癌中CD8 T细胞的浸润。
Commun Biol. 2025 May 8;8(1):711. doi: 10.1038/s42003-025-08108-6.
6
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.BIN1 通过失活 c-MYC 和 EGFR/MAPK 信号通路逆转非小细胞肺癌中的 PD-L1 介导的免疫逃逸。
Oncogene. 2017 Nov 9;36(45):6235-6243. doi: 10.1038/onc.2017.217. Epub 2017 Jul 17.
7
Low-dose SAHA enhances CD8 T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer.低剂量SAHA通过提高非小细胞肺癌中MHC I的表达来增强CD8 T细胞介导的抗肿瘤免疫力。
Cell Oncol (Dordr). 2025 Feb;48(1):249-264. doi: 10.1007/s13402-024-00989-9. Epub 2024 Sep 16.
8
EGFR mutations induce the suppression of CD8 T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.表皮生长因子受体突变通过 ERK1/2-p90RSK-TGF-β 轴诱导非小细胞肺癌中 CD8 T 细胞的抑制和抗 PD-1 耐药。
J Transl Med. 2024 Jul 14;22(1):653. doi: 10.1186/s12967-024-05456-5.
9
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
10
ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3.ASCC3 通过 CAND1 介导的 STAT3 泛素化抑制作用损害 I 型干扰素反应,促进非小细胞肺癌的免疫抑制和进展。
J Immunother Cancer. 2023 Dec 26;11(12):e007766. doi: 10.1136/jitc-2023-007766.

引用本文的文献

1
Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives.肿瘤微环境中的铁死亡:机制、进展与治疗前景
Front Oncol. 2025 Aug 22;15:1650219. doi: 10.3389/fonc.2025.1650219. eCollection 2025.
2
The novel functions of chemokines in lung cancer progression.趋化因子在肺癌进展中的新功能。
Front Immunol. 2025 Jun 18;16:1607225. doi: 10.3389/fimmu.2025.1607225. eCollection 2025.

本文引用的文献

1
Lysine vitcylation is a vitamin C-derived protein modification that enhances STAT1-mediated immune response.赖氨酸维生素C化是一种源自维生素C的蛋白质修饰,可增强STAT1介导的免疫反应。
Cell. 2025 Apr 3;188(7):1858-1877.e21. doi: 10.1016/j.cell.2025.01.043. Epub 2025 Feb 28.
2
Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10.基于 IFN-γ 和 TNF-α 协同诱导高表达 CXCL10,构建了自我驾驶的抗-αFR CAR 工程化 NK 细胞。
Neoplasia. 2024 Dec;58:101065. doi: 10.1016/j.neo.2024.101065. Epub 2024 Oct 3.
3
ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
ALKBH5 通过调节肿瘤与巨噬细胞之间的相互作用促进非小细胞肺癌的进展和对抗 PD-L1 治疗的敏感性。
J Exp Clin Cancer Res. 2024 Jun 14;43(1):164. doi: 10.1186/s13046-024-03073-0.
4
CD8 T cell-based cancer immunotherapy.基于 CD8 T 细胞的癌症免疫疗法。
J Transl Med. 2024 Apr 29;22(1):394. doi: 10.1186/s12967-024-05134-6.
5
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.可溶性免疫检查点因子反映了抗肿瘤免疫的衰竭和对 PD-1 阻断的反应。
J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318.
6
Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11/GSH/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation.硫化氢通过 Keap1 S-巯基化和 Nrf2 激活 SLC7A11/GSH/GPx4 通路保护心肌细胞免受阿霉素诱导的铁死亡。
Redox Biol. 2024 Apr;70:103066. doi: 10.1016/j.redox.2024.103066. Epub 2024 Jan 29.
7
Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8T cells.肿瘤分泌的 FGF21 通过重编 CD8T 细胞的胆固醇代谢来发挥免疫抑制作用。
Cell Metab. 2024 Mar 5;36(3):630-647.e8. doi: 10.1016/j.cmet.2024.01.005. Epub 2024 Feb 2.
8
G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K/Akt Activation in Bladder Cancer.G3BP1 和 SLU7 通过激活 PI3K/Akt 下调 MHC-I 共同促进膀胱癌的免疫逃逸。
Adv Sci (Weinh). 2024 Feb;11(7):e2305922. doi: 10.1002/advs.202305922. Epub 2023 Dec 12.
9
Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.肿瘤细胞内在的 SETD2 失活通过 NR2F1-STAT1 通路使癌细胞对免疫检查点阻断敏感。
J Immunother Cancer. 2023 Dec 6;11(12):e007678. doi: 10.1136/jitc-2023-007678.
10
The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies.STAT3 和 STAT1 在癌症生物学中的互补作用:对肿瘤发病机制和治疗策略的深入了解。
Front Immunol. 2023 Nov 8;14:1265818. doi: 10.3389/fimmu.2023.1265818. eCollection 2023.